{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T00:04:09Z","timestamp":1794960249017,"version":"4.9.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T00:00:00Z","timestamp":1681948800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T00:00:00Z","timestamp":1681948800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","award":["20FC1030"],"award-info":[{"award-number":["20FC1030"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["20K07892"],"award-info":[{"award-number":["20K07892"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>White blood cell (WBC) count profiles in anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder (AQP4-NMOSD) and anti-myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) are still unknown. This study evaluated the total WBC count, differential WBC counts, monocyte-to-lymphocyte ratio (MLR), and neutrophil-to-lymphocyte ratio (NLR) in patients with these diseases within three months from an attack before acute treatment or relapse prevention and compared the profiles with those in matched volunteers or in multiple sclerosis (MS) patients. AQP4-NMOSD patients (n\u2009=\u200913) had a higher neutrophil count (p\u2009=\u20090.0247), monocyte count (p\u2009=\u20090.0359), MLR (p\u2009=\u20090.0004), and NLR (p\u2009=\u20090.0037) and lower eosinophil (p\u2009=\u20090.0111) and basophil (p\u2009=\u20090.0283) counts than those of AQP4-NMOSD-matched volunteers (n\u2009=\u200965). Moreover, patients with MOGAD (n\u2009=\u200926) had a higher overall WBC count (p\u2009=\u20090.0001), neutrophil count (p\u2009&lt;\u20090.0001), monocyte count (p\u2009=\u20090.0191), MLR (p\u2009=\u20090.0320), and NLR (p\u2009=\u20090.0002) than those of MOGAD-matched volunteers (n\u2009=\u2009130). The three demyelinating diseases showed similar levels of the total and differential WBC counts; however, MOGAD and MS showed different structures in the hierarchical clustering and distributions on a two-dimensional canonical plot using differential WBC counts from the other three groups. WBC count profiles were similar in patients with MOGAD and MS but differed from profiles in matched volunteers or patients with AQP4-NMOSD.<\/jats:p>","DOI":"10.1038\/s41598-023-33827-3","type":"journal-article","created":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T17:01:26Z","timestamp":1682010086000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["White blood cell count profiles in anti-aquaporin-4 antibody seropositive neuromyelitis optica spectrum disorder and anti-myelin oligodendrocyte glycoprotein antibody-associated disease"],"prefix":"10.1038","volume":"13","author":[{"given":"Tetsuya","family":"Akaishi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuro","family":"Misu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuo","family":"Fujihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kumi","family":"Nakaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Nakaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mana","family":"Kogure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rieko","family":"Hatanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumi","family":"Itabashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ikumi","family":"Kanno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimihiko","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiyuki","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juichi","family":"Fujimori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiki","family":"Takai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhei","family":"Nishiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadashi","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Aoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiro","family":"Nakashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Hozawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,20]]},"reference":[{"key":"33827_CR1","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1212\/wnl.0000000000001729","volume":"85","author":"DM Wingerchuk","year":"2015","unstructured":"Wingerchuk, D. M. et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 85, 177\u2013189. https:\/\/doi.org\/10.1212\/wnl.0000000000001729 (2015).","journal-title":"Neurology"},{"key":"33827_CR2","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1001\/jamaneurol.2013.5857","volume":"71","author":"J Kitley","year":"2014","unstructured":"Kitley, J. et al. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: A comparative study. JAMA Neurol. 71, 276\u2013283. https:\/\/doi.org\/10.1001\/jamaneurol.2013.5857 (2014).","journal-title":"JAMA Neurol."},{"key":"33827_CR3","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/s1474-4422(22)00431-8","volume":"22","author":"B Banwell","year":"2023","unstructured":"Banwell, B. et al. Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria. Lancet Neurol. 22, 268\u2013282. https:\/\/doi.org\/10.1016\/s1474-4422(22)00431-8 (2023).","journal-title":"Lancet Neurol."},{"key":"33827_CR4","doi-asserted-by":"publisher","first-page":"169","DOI":"10.7861\/clinmedicine.19-2-169","volume":"19","author":"S Huda","year":"2019","unstructured":"Huda, S. et al. Neuromyelitis optica spectrum disorders. Clin. Med. (Lond) 19, 169\u2013176. https:\/\/doi.org\/10.7861\/clinmedicine.19-2-169 (2019).","journal-title":"Clin. Med. (Lond)"},{"key":"33827_CR5","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1212\/wnl.0000000000001367","volume":"84","author":"HJ Kim","year":"2015","unstructured":"Kim, H. J. et al. MRI characteristics of neuromyelitis optica spectrum disorder: An international update. Neurology 84, 1165\u20131173. https:\/\/doi.org\/10.1212\/wnl.0000000000001367 (2015).","journal-title":"Neurology"},{"key":"33827_CR6","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1212\/01.wnl.0000254502.87233.9a","volume":"68","author":"DM Wingerchuk","year":"2007","unstructured":"Wingerchuk, D. M., Pittock, S. J., Lucchinetti, C. F., Lennon, V. A. & Weinshenker, B. G. A secondary progressive clinical course is uncommon in neuromyelitis optica. Neurology 68, 603\u2013605. https:\/\/doi.org\/10.1212\/01.wnl.0000254502.87233.9a (2007).","journal-title":"Neurology"},{"key":"33827_CR7","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1097\/icu.0000000000000703","volume":"31","author":"KB Holroyd","year":"2020","unstructured":"Holroyd, K. B., Manzano, G. S. & Levy, M. Update on neuromyelitis optica spectrum disorder. Curr. Opin. Ophthalmol. 31, 462\u2013468. https:\/\/doi.org\/10.1097\/icu.0000000000000703 (2020).","journal-title":"Curr. Opin. Ophthalmol."},{"key":"33827_CR8","doi-asserted-by":"publisher","first-page":"13890","DOI":"10.1038\/s41598-020-70919-w","volume":"10","author":"T Akaishi","year":"2020","unstructured":"Akaishi, T. et al. Progressive patterns of neurological disability in multiple sclerosis and neuromyelitis optica spectrum disorders. Sci. Rep. 10, 13890. https:\/\/doi.org\/10.1038\/s41598-020-70919-w (2020).","journal-title":"Sci. Rep."},{"key":"33827_CR9","doi-asserted-by":"publisher","unstructured":"Akaishi, T. et al. Progression pattern of neurological disability with respect to clinical attacks in anti-MOG antibody-associated disorders. J. Neuroimmunol. 351, 577467. https:\/\/doi.org\/10.1016\/j.jneuroim.2020.577467 (2021).","DOI":"10.1016\/j.jneuroim.2020.577467"},{"key":"33827_CR10","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1001\/archneurol.2012.1051","volume":"69","author":"EW Radue","year":"2012","unstructured":"Radue, E. W. et al. Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis. Arch Neurol. 69, 1259\u20131269. https:\/\/doi.org\/10.1001\/archneurol.2012.1051 (2012).","journal-title":"Arch Neurol."},{"key":"33827_CR11","doi-asserted-by":"publisher","unstructured":"Wang, L. et al. The alteration of circulating lymphocyte subsets during tacrolimus therapy in neuromyelitis optica spectrum disorder and its correlation with clinical outcomes. Front. Neurol. 12, 816721. https:\/\/doi.org\/10.3389\/fneur.2021.816721 (2021).","DOI":"10.3389\/fneur.2021.816721"},{"key":"33827_CR12","doi-asserted-by":"publisher","unstructured":"Traub, J., H\u00e4usser-Kinzel, S. & Weber, M. S. Differential effects of MS therapeutics on B cells-implications for their use and failure in AQP4-positive NMOSD patients. Int. J. Mol. Sci. 21, 1. https:\/\/doi.org\/10.3390\/ijms21145021 (2020).","DOI":"10.3390\/ijms21145021"},{"key":"33827_CR13","doi-asserted-by":"publisher","first-page":"4522","DOI":"10.1007\/s00415-020-10235-5","volume":"268","author":"T Holm\u00f8y","year":"2021","unstructured":"Holm\u00f8y, T., H\u00f8glund, R. A., Illes, Z., Myhr, K. M. & Torkildsen, \u00d8. Recent progress in maintenance treatment of neuromyelitis optica spectrum disorder. J. Neurol. 268, 4522\u20134536. https:\/\/doi.org\/10.1007\/s00415-020-10235-5 (2021).","journal-title":"J. Neurol."},{"key":"33827_CR14","doi-asserted-by":"publisher","first-page":"22357","DOI":"10.1038\/s41598-021-01942-8","volume":"11","author":"T Akaishi","year":"2021","unstructured":"Akaishi, T. et al. White blood cell count profiles in multiple sclerosis during attacks before the initiation of acute and chronic treatments. Sci. Rep. 11, 22357. https:\/\/doi.org\/10.1038\/s41598-021-01942-8 (2021).","journal-title":"Sci. Rep."},{"key":"33827_CR15","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/s1474-4422(17)30470-2","volume":"17","author":"AJ Thompson","year":"2018","unstructured":"Thompson, A. J. et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 17, 162\u2013173. https:\/\/doi.org\/10.1016\/s1474-4422(17)30470-2 (2018).","journal-title":"Lancet Neurol."},{"key":"33827_CR16","doi-asserted-by":"publisher","first-page":"65","DOI":"10.2188\/jea.JE20190271","volume":"31","author":"A Hozawa","year":"2021","unstructured":"Hozawa, A. et al. Study profile of the Tohoku medical megabank community-based cohort study. J. Epidemiol. 31, 65\u201376. https:\/\/doi.org\/10.2188\/jea.JE20190271 (2021).","journal-title":"J. Epidemiol."},{"key":"33827_CR17","doi-asserted-by":"publisher","first-page":"493","DOI":"10.2188\/jea.JE20150268","volume":"26","author":"S Kuriyama","year":"2016","unstructured":"Kuriyama, S. et al. The Tohoku Medical Megabank project: Design and mission. J. Epidemiol. 26, 493\u2013511. https:\/\/doi.org\/10.2188\/jea.JE20150268 (2016).","journal-title":"J. Epidemiol."},{"key":"33827_CR18","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1620\/tjem.210.307","volume":"210","author":"T Takahashi","year":"2006","unstructured":"Takahashi, T. et al. Establishment of a new sensitive assay for anti-human aquaporin-4 antibody in neuromyelitis optica. Tohoku J. Exp. Med. 210, 307\u2013313. https:\/\/doi.org\/10.1620\/tjem.210.307 (2006).","journal-title":"Tohoku J. Exp. Med."},{"key":"33827_CR19","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1093\/brain\/awm062","volume":"130","author":"T Takahashi","year":"2007","unstructured":"Takahashi, T. et al. Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: A study on antibody titre. Brain 130, 1235\u20131243. https:\/\/doi.org\/10.1093\/brain\/awm062 (2007).","journal-title":"Brain"},{"key":"33827_CR20","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/s0895-4356(00)00314-0","volume":"54","author":"R Bender","year":"2001","unstructured":"Bender, R. & Lange, S. Adjusting for multiple testing\u2013when and how?. J. Clin. Epidemiol. 54, 343\u2013349. https:\/\/doi.org\/10.1016\/s0895-4356(00)00314-0 (2001).","journal-title":"J. Clin. Epidemiol."},{"key":"33827_CR21","doi-asserted-by":"publisher","first-page":"573","DOI":"10.7326\/0003-4819-147-8-200710160-00010","volume":"147","author":"E von Elm","year":"2007","unstructured":"von Elm, E. et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med. 147, 573\u2013577. https:\/\/doi.org\/10.7326\/0003-4819-147-8-200710160-00010 (2007).","journal-title":"Ann Intern Med."},{"key":"33827_CR22","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/s12964-019-0471-y","volume":"17","author":"Y Li","year":"2019","unstructured":"Li, Y. et al. The regulatory roles of neutrophils in adaptive immunity. Cell Commun. Signal 17, 147. https:\/\/doi.org\/10.1186\/s12964-019-0471-y (2019).","journal-title":"Cell Commun. Signal"},{"key":"33827_CR23","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1038\/nri.2016.49","volume":"16","author":"S de Oliveira","year":"2016","unstructured":"de Oliveira, S., Rosowski, E. E. & Huttenlocher, A. Neutrophil migration in infection and wound repair: Going forward in reverse. Nat. Rev. Immunol. 16, 378\u2013391. https:\/\/doi.org\/10.1038\/nri.2016.49 (2016).","journal-title":"Nat. Rev. Immunol."},{"key":"33827_CR24","doi-asserted-by":"publisher","first-page":"355","DOI":"10.3389\/fncel.2019.00355","volume":"13","author":"A Fani Maleki","year":"2019","unstructured":"Fani Maleki, A. & Rivest, S. Innate immune cells: Monocytes, monocyte-derived macrophages and microglia as therapeutic targets for Alzheimer\u2019s disease and multiple sclerosis. Front Cell Neurosci. 13, 355. https:\/\/doi.org\/10.3389\/fncel.2019.00355 (2019).","journal-title":"Front Cell Neurosci."},{"key":"33827_CR25","doi-asserted-by":"publisher","unstructured":"Woodberry, T., Bouffler, S. E., Wilson, A. S., Buckland, R. L. & Br\u00fcstle, A. The emerging role of neutrophil granulocytes in multiple sclerosis. J. Clin. Med. 7. https:\/\/doi.org\/10.3390\/jcm7120511 (2018).","DOI":"10.3390\/jcm7120511"},{"key":"33827_CR26","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.jneuroim.2018.03.016","volume":"319","author":"T Akaishi","year":"2018","unstructured":"Akaishi, T., Takahashi, T. & Nakashima, I. Peripheral blood monocyte count at onset may affect the prognosis in multiple sclerosis. J. Neuroimmunol. 319, 37\u201340. https:\/\/doi.org\/10.1016\/j.jneuroim.2018.03.016 (2018).","journal-title":"J. Neuroimmunol."},{"key":"33827_CR27","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1146\/annurev.immunol.26.021607.090326","volume":"26","author":"NV Serbina","year":"2008","unstructured":"Serbina, N. V., Jia, T., Hohl, T. M. & Pamer, E. G. Monocyte-mediated defense against microbial pathogens. Annu. Rev. Immunol. 26, 421\u2013452. https:\/\/doi.org\/10.1146\/annurev.immunol.26.021607.090326 (2008).","journal-title":"Annu. Rev. Immunol."},{"key":"33827_CR28","doi-asserted-by":"publisher","first-page":"205521731881318","DOI":"10.1177\/2055217318813183","volume":"4","author":"IC Hasselbalch","year":"2018","unstructured":"Hasselbalch, I. C. et al. The neutrophil-to-lymphocyte ratio is associated with multiple sclerosis. Mult. Scler. J. Exp. Transl. Clin. 4, 2055217318813183. https:\/\/doi.org\/10.1177\/2055217318813183 (2018).","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"key":"33827_CR29","doi-asserted-by":"publisher","first-page":"269","DOI":"10.7754\/clin.lab.2014.140927","volume":"61","author":"H Fu","year":"2015","unstructured":"Fu, H. et al. Neutrophil- and platelet-to-lymphocyte ratios are correlated with disease activity in rheumatoid arthritis. Clin. Lab. 61, 269\u2013273. https:\/\/doi.org\/10.7754\/clin.lab.2014.140927 (2015).","journal-title":"Clin. Lab."},{"key":"33827_CR30","doi-asserted-by":"publisher","first-page":"213","DOI":"10.4149\/bll_2015_041","volume":"116","author":"G Acarturk","year":"2015","unstructured":"Acarturk, G. et al. Neutrophil-to-lymphocyte ratio in inflammatory bowel disease\u2014as a new predictor of disease severity. Bratisl. Lek Listy 116, 213\u2013217. https:\/\/doi.org\/10.4149\/bll_2015_041 (2015).","journal-title":"Bratisl. Lek Listy"},{"key":"33827_CR31","doi-asserted-by":"publisher","first-page":"702","DOI":"10.3332\/ecancer.2016.702","volume":"10","author":"SS Faria","year":"2016","unstructured":"Faria, S. S. et al. The neutrophil-to-lymphocyte ratio: A narrative review. Ecancermedicalscience 10, 702. https:\/\/doi.org\/10.3332\/ecancer.2016.702 (2016).","journal-title":"Ecancermedicalscience"},{"key":"33827_CR32","doi-asserted-by":"publisher","unstructured":"Huang, W. C. et al. Neutrophil-to-lymphocyte ratio and monocyte-to-lymphocyte ratio are associated with a 2-year relapse in patients with multiple sclerosis. Mult. Scler. Relat. Disord. 58, 103514. https:\/\/doi.org\/10.1016\/j.msard.2022.103514 (2022).","DOI":"10.1016\/j.msard.2022.103514"},{"key":"33827_CR33","doi-asserted-by":"publisher","first-page":"700","DOI":"10.3109\/00207454.2015.1050492","volume":"126","author":"S Demirci","year":"2016","unstructured":"Demirci, S., Demirci, S., Kutluhan, S., Koyuncuoglu, H. R. & Yurekli, V. A. The clinical significance of the neutrophil-to-lymphocyte ratio in multiple sclerosis. Int. J. Neurosci. 126, 700\u2013706. https:\/\/doi.org\/10.3109\/00207454.2015.1050492 (2016).","journal-title":"Int. J. Neurosci."},{"key":"33827_CR34","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.jcma.2015.08.010","volume":"79","author":"I Guzel","year":"2016","unstructured":"Guzel, I., Mungan, S., Oztekin, Z. N. & Ak, F. Is there an association between the Expanded Disability Status Scale and inflammatory markers in multiple sclerosis?. J. Chin. Med. Assoc. 79, 54\u201357. https:\/\/doi.org\/10.1016\/j.jcma.2015.08.010 (2016).","journal-title":"J. Chin. Med. Assoc."},{"key":"33827_CR35","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1080\/00207454.2017.1418342","volume":"128","author":"Y Huang","year":"2018","unstructured":"Huang, Y. et al. The clinical significance of neutrophil-to-lymphocyte ratio and monocyte-to-lymphocyte ratio in Guillain-Barr\u00e9 syndrome. Int. J. Neurosci. 128, 729\u2013735. https:\/\/doi.org\/10.1080\/00207454.2017.1418342 (2018).","journal-title":"Int. J. Neurosci."},{"key":"33827_CR36","doi-asserted-by":"publisher","first-page":"2595","DOI":"10.1016\/j.jstrokecerebrovasdis.2017.06.019","volume":"26","author":"H Ren","year":"2017","unstructured":"Ren, H., Liu, X., Wang, L. & Gao, Y. Lymphocyte-to-monocyte ratio: A novel predictor of the prognosis of acute ischemic stroke. J. Stroke Cerebrovasc. Dis. 26, 2595\u20132602. https:\/\/doi.org\/10.1016\/j.jstrokecerebrovasdis.2017.06.019 (2017).","journal-title":"J. Stroke Cerebrovasc. Dis."},{"key":"33827_CR37","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s12883-019-1245-2","volume":"19","author":"CC Hemond","year":"2019","unstructured":"Hemond, C. C., Glanz, B. I., Bakshi, R., Chitnis, T. & Healy, B. C. The neutrophil-to-lymphocyte and monocyte-to-lymphocyte ratios are independently associated with neurological disability and brain atrophy in multiple sclerosis. BMC Neurol. 19, 23. https:\/\/doi.org\/10.1186\/s12883-019-1245-2 (2019).","journal-title":"BMC Neurol."},{"key":"33827_CR38","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/1742-2094-5-27","volume":"5","author":"WA Sheremata","year":"2008","unstructured":"Sheremata, W. A. et al. Evidence of platelet activation in multiple sclerosis. J. Neuroinflammation 5, 27. https:\/\/doi.org\/10.1186\/1742-2094-5-27 (2008).","journal-title":"J. Neuroinflammation"},{"key":"33827_CR39","doi-asserted-by":"publisher","unstructured":"Sechi, E. et al. Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): A review of clinical and MRI features, diagnosis, and management. Front. Neurol. 13, 885218. https:\/\/doi.org\/10.3389\/fneur.2022.885218 (2022).","DOI":"10.3389\/fneur.2022.885218"},{"key":"33827_CR40","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1136\/jnnp-2018-317969","volume":"89","author":"K Kaneko","year":"2018","unstructured":"Kaneko, K. et al. CSF cytokine profile in MOG-IgG+ neurological disease is similar to AQP4-IgG+ NMOSD but distinct from MS: A cross-sectional study and potential therapeutic implications. J. Neurol. Neurosurg. Psychiatry 89, 927\u2013936. https:\/\/doi.org\/10.1136\/jnnp-2018-317969 (2018).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"33827_CR41","doi-asserted-by":"publisher","unstructured":"Akaishi, T. et al. Risk factors of attacks in neuromyelitis optica spectrum disorders. J. Neuroimmunol. 343, 577236. https:\/\/doi.org\/10.1016\/j.jneuroim.2020.577236 (2020).","DOI":"10.1016\/j.jneuroim.2020.577236"},{"key":"33827_CR42","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1001\/archneur.65.5.629","volume":"65","author":"SJ Pittock","year":"2008","unstructured":"Pittock, S. J. & Lennon, V. A. Aquaporin-4 autoantibodies in a paraneoplastic context. Arch. Neurol. 65, 629\u2013632. https:\/\/doi.org\/10.1001\/archneur.65.5.629 (2008).","journal-title":"Arch. Neurol."},{"key":"33827_CR43","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1177\/1352458517731914","volume":"24","author":"M Sep\u00falveda","year":"2018","unstructured":"Sep\u00falveda, M. et al. Clinical profile of patients with paraneoplastic neuromyelitis optica spectrum disorder and aquaporin-4 antibodies. Mult. Scler. 24, 1753\u20131759. https:\/\/doi.org\/10.1177\/1352458517731914 (2018).","journal-title":"Mult. Scler."},{"key":"33827_CR44","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1007\/s00415-020-10377-6","volume":"268","author":"T Akaishi","year":"2021","unstructured":"Akaishi, T. et al. Impact of comorbid Sj\u00f6gren syndrome in anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorders. J. Neurol. 268, 1938\u20131944. https:\/\/doi.org\/10.1007\/s00415-020-10377-6 (2021).","journal-title":"J. Neurol."},{"key":"33827_CR45","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1001\/archneurol.2007.17","volume":"65","author":"SJ Pittock","year":"2008","unstructured":"Pittock, S. J. et al. Neuromyelitis optica and non organ-specific autoimmunity. Arch. Neurol. 65, 78\u201383. https:\/\/doi.org\/10.1001\/archneurol.2007.17 (2008).","journal-title":"Arch. Neurol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-33827-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-33827-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-33827-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T17:05:34Z","timestamp":1682010334000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-33827-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,20]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["33827"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-33827-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,20]]},"assertion":[{"value":"2 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"K. Fujihara received speaker honoraria and travel funding from Bayer, Biogen Japan, Eisai, Mitsubishi Tanabe, Novartis, Astellas, Takeda, Asahi Kasei Medical, Daiichi Sankyo, and Nihon Pharmaceutical and received research support from Bayer, Biogen, Asahi Kasei Medical, The Chemo-Sero-Therapeutic Research Institute, Teva, Mitsubishi Tanabe Pharma, Teijin, Chugai, Ono, Nihon Pharmaceutical, and Genzyme. I. Nakashima received speaker honoraria and travel funding from Mitsubishi Tanabe Pharma, Biogen Japan, and Novartis Pharmaceuticals and received research support from LSI Medience Corporation. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6481"}}